Drug intelligence / Profile preview

LBP-PA01

Development stage: Unknown
Lead developer: Locus Biosciences
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Inhalation, Intravenous

Overview

**LBP-PA01** is an AI-designed, engineered six-bacteriophage cocktail from Locus Biosciences for selective treatment of antibiotic-resistant *Pseudomonas aeruginosa* infections. The product incorporates phages engineered to express CRISPR-Cas3 and is intended to kill *P. aeruginosa*, including biofilm-associated bacteria, through bacteriophage-mediated antibacterial activity. It is being advanced for *P. aeruginosa* hospital-acquired pneumonia and ventilator-associated pneumonia; NIAID funding supports a planned Phase 1b proof-of-concept study evaluating safety, efficacy, and dosing. ([academic.oup.com](https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.161/7988358))

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on LBP-PA01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBP-PA01.

Explore the full profile